Evidence map›Paper›PMID 40337847›Full record

ArticleJournal of cell science2025

PI31 is a positive regulator of 20S immunoproteasome assembly.

Jason Wang, Abbey Kjellgren, George N DeMartino

Abstract read
In one paragraph

Article in Journal of cell science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Plasticity in the structure and assembly of proteasomes.The Journal of biological chemistry · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jason WangDepartment of Physiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9040, USA.
Abbey KjellgrenDepartment of Physiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9040, USA.
George N DeMartinoDepartment of Physiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9040, USA.ORCID 0000-0001-8718-783X

Funding

PI31: a regulator of proteasome adaptation to stressR01GM129088 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI DEMARTINO, GEORGE N. · 2019 to 2022
$1.3M
NIGMS NIH HHS R01 GM129088NIH HHS GM 129088The University of Texas Southwestern Medical Center
6 · The paper itself

Abstract

Proteasome inhibitor of 31,000 Da (PI31) is a 20S proteasome-binding protein originally identified as an inhibitor of in vitro 20S proteasome activity. Although recent studies have elucidated a detailed structural basis for this inhibitory activity, the physiological significance of PI31-mediated proteasome inhibition remains uncertain, and multiple alternative cellular roles for PI31 have been described. Here, we report a role for PI31 as a positive regulator for assembly of the 20S immunoproteasome (20Si), a compositionally and functionally distinct isoform of the proteasome that is poorly inhibited by PI31. Genetic ablation of PI31 in mammalian cells had no effect on the cellular content or activity of constitutively expressed proteasomes but reduced the cellular content and activity of interferon-γ-induced immunoproteasomes. This selective effect results from impaired 20Si assembly, evidenced by the accumulation of 20Si assembly intermediates. Our results highlight a distinction in the assembly pathways of constitutive proteasomes and immunoproteasomes and indicate that PI31 plays a chaperone-like role in the selective assembly of 20S immunoproteasomes.

Indexed as

Proteasome Endopeptidase ComplexAnimalsHumansInterferon-gammaMiceProteasome InhibitorsInterferon-gammaProteasome Endopeptidase ComplexProteasome InhibitorsImmunoproteasomePI31ProteasomeProteasome regulatorProtein degradation

Identifiers

PMID40337847
PMCPMC12148024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.